Latest Period
Q4 2025
Security Snapshot
SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) Institutional Ownership
CUSIP: 78397T202
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
48
Shares (Excl. Options)
36,342,111
Price
$3.74
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place.
- Type / Class
- Equity / Common Stock, par value $0.0001 per share
- Symbol
- SABS on Nasdaq
- Shares outstanding
- 67,297,118
- Price per share
- $3.90
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 36,342,111
- Total reported value
- $135,919,535
- % of total 13F portfolios
- 0%
- Share change
- +6,119,671
- Value change
- +$25,718,819
- Number of holders
- 48
- Price from insider filings
- $3.90
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 78397T202.
- 48 institutions reported positions in Q4 2025.
- 8 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 48 to 5 between Q4 2025 and Q1 2026.
- Reported value moved from $135,919,535 to $2,382,204.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 48 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 78397T202?
CUSIP 78397T202 identifies SABS - SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 78397T202:
Significant Owners of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $54,973,720 | 25,931,000 | Vivo Opportunity Fund Holdings, L.P. | 29 Sep 2025 | |||
| RA CAPITAL MANAGEMENT, L.P. | 9.9% | 0% | $30,195,359 | +$8,858,028 | 7,311,225 | +42% | RA Capital Management, L.P. | 19 Mar 2026 |
| Woodline Partners LP | 9.9% | $14,323,021 | 7,125,881 | Woodline Partners LP | 30 Sep 2025 | |||
| BIOTECHNOLOGY VALUE FUND L P | 9.1% | -8.9% | $18,761,910 | -$1,598,505 | 4,761,906 | -7.9% | BVF PARTNERS L P/IL | 31 Dec 2025 |
| Commodore Capital LP | 9.9% | $9,588,711 | 4,522,977 | Commodore Capital LP | 26 Sep 2025 | |||
| PERCEPTIVE ADVISORS LLC | 7.3% | $13,088,916 | 3,471,861 | Perceptive Advisors LLC | 14 Jan 2026 | |||
| MILLENNIUM MANAGEMENT LLC | 5.1% | $13,385,397 | 3,432,153 | Millennium Management LLC | 24 Apr 2026 | |||
| RTW INVESTMENTS, LP | 3.2% | -68% | $6,253,970 | +$2,218,090 | 1,587,302 | +55% | RTW Investments, LP | 31 Dec 2025 |
As of 31 Dec 2025, 48 institutional investors reported holding 36,342,111 shares of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS). This represents 54% of the company’s total 67,297,118 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) together control 54% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Vivo Capital, LLC | 17% | 11,420,000 | 0% | 2.8% | $42,710,800 |
| Commodore Capital LP | 6.5% | 4,401,500 | 0% | 1.1% | $16,461,610 |
| RA CAPITAL MANAGEMENT, L.P. | 6.5% | 4,401,500 | 0% | 0.17% | $16,461,610 |
| Woodline Partners LP | 4.2% | 2,850,881 | 0% | 0.04% | $10,662,295 |
| Spruce Street Capital LP | 3.3% | 2,198,502 | 0% | 2.7% | $8,222,397 |
| Sessa Capital IM, L.P. | 3.3% | 2,198,457 | 0% | 0.16% | $8,222,229 |
| Blackstone Inc. | 3.2% | 2,143,585 | 0.04% | $8,017,008 | |
| VANGUARD GROUP INC | 2.7% | 1,847,136 | +405% | 0% | $6,908,288 |
| PERCEPTIVE ADVISORS LLC | 1.2% | 803,210 | 0.06% | $3,004,005 | |
| Propel Bio Management, LLC | 0.97% | 652,881 | 2.1% | $2,441,775 | |
| Jefferies Financial Group Inc. | 0.86% | 580,328 | 0.02% | $2,170,427 | |
| Balyasny Asset Management L.P. | 0.71% | 475,439 | 0% | $1,778,142 | |
| MILLENNIUM MANAGEMENT LLC | 0.48% | 324,090 | 0% | $1,212,097 | |
| HB Wealth Management, LLC | 0.46% | 307,500 | 0% | 0.01% | $1,150,050 |
| AMERIPRISE FINANCIAL INC | 0.42% | 283,645 | 0% | $1,060,833 | |
| MARSHALL WACE, LLP | 0.35% | 236,460 | 0% | $884,360 | |
| Simplify Asset Management Inc. | 0.31% | 208,227 | 0.01% | $778,769 | |
| AWM Investment Company, Inc. | 0.3% | 200,000 | 0% | 0.07% | $748,000 |
| STEMPOINT CAPITAL LP | 0.22% | 146,558 | 0.09% | $548,127 | |
| GEODE CAPITAL MANAGEMENT, LLC | 0.18% | 119,517 | +39% | 0% | $447,037 |
| ExodusPoint Capital Management, LP | 0.13% | 86,113 | 0% | $322,063 | |
| GOLDMAN SACHS GROUP INC | 0.08% | 51,348 | +358% | 0% | $192,042 |
| Pathstone Holdings, LLC | 0.08% | 50,650 | 0% | 0% | $189,433 |
| OMERS ADMINISTRATION Corp | 0.06% | 42,000 | 0% | $157,080 | |
| Qube Research & Technologies Ltd | 0.05% | 31,147 | 0% | $116,490 |
Institutional Holders of SAB Biotherapeutics, Inc. - Common Stock, par value $0.0001 per share (SABS) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 621,912 | $2,382,204 | +$289,546 | $3.83 | 5 |
| 2025 Q4 | 36,342,111 | $135,919,535 | +$25,718,819 | $3.74 | 48 |
| 2025 Q3 | 28,023,938 | $56,328,113 | +$52,469,483 | $2.01 | 34 |
| 2025 Q2 | 1,923,874 | $3,369,565 | -$378,633 | $1.76 | 25 |
| 2025 Q1 | 2,209,552 | $2,994,479 | -$1,776,863 | $1.36 | 26 |
| 2024 Q4 | 2,652,300 | $10,189,778 | -$1,266,185 | $3.79 | 26 |
| 2024 Q3 | 3,141,736 | $8,482,377 | +$68,507 | $2.70 | 24 |
| 2024 Q2 | 3,127,151 | $9,694,108 | -$923,501 | $3.10 | 21 |
| 2024 Q1 | 3,339,666 | $15,162,138 | -$15,603,353 | $4.54 | 23 |
| 2023 Q4 | 8,791,109 | $6,055,351 | +$6,055,351 | $0.69 | 3 |